Induction of β-Glucuronidase Release by Cytostatic Agents in Small Tumors

被引：13

作者：

Antunes, Ines F. ^{[1
]}

Haisma, Hidde J. ^{[2
]}

Elsinga, Philip H. ^{[1
]}

Di Gialleonardo, Valentina ^{[1
]}

van Waarde, Aren ^{[1
]}

Willemsen, Antoon T. M. ^{[1
]}

Dierckx, Rudi A. ^{[1
]}

de Vries, Erik F. J. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, NL-9700 RB Groningen, Netherlands

[2] Univ Groningen, Univ Ctr Pharm, Dept Pharmaceut Gene Modulat, NL-9713 AV Groningen, Netherlands

来源：

MOLECULAR PHARMACEUTICS | 2012年 / 9卷 / 11期

关键词：

beta-glucuronidase; prodrug; cytostatics; F-18]FEAnGA; small tumors; treatment; NECROSIS-FACTOR-ALPHA; BLOOD-FLOW; PRODRUG; THYMUS; CHEMOTHERAPY; INJECTION; MECHANISM; EFFICACY;

D O I：

10.1021/mp300327w

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Extracellular beta-glucuronidase (beta-GUS) in tumors has been investigated as a target enzyme for prodrug therapy. However, despite encouraging preclinical results, animal studies also indicate that the success of prodrug therapy might be limited by the insufficient prodrug-converting enzyme activity, especially in small tumors. We hypothesized that a single dose of a cytostatic drug might induce the release of beta-GUS in small tumors, resulting in increased levels of extracellular beta-GUS and consequently a higher efficacy of the prodrug treatment. Here we examine the extent of beta-GUS release in small C6 glioma tumors after a single treatment of doxorubicin (DOX), carmustine (BCNU) and tumor necrosis factor alpha (TNF-alpha) with positron emission tomography (PET) and the tracer 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-beta-D-glucopyronuronate, [F-18]FEAnGA, which has been proven to be selective for extracellular beta-GUS. Induction of beta-GUS release was first investigated in cultured C6 glioma cells. In addition, a [F-18]FEAnGA PET study was performed in C6 tumor-bearing rats 48 h after a single treatment with different cytostatics to evaluate the extent of beta-glucuronidase release. The cleavage of [F-18]FEAnGA by beta-GUS was analyzed in tumor homogenates. The induction of tumor necrosis and leukocyte infiltration was confirmed by histochemical analysis and flow cytometry. The in vitro studies indicated that all treatments resulted in a decline of viable cells and an increase of extracellular beta-GUS activity. PET studies confirmed that beta-GUS was released in vivo and the distribution volume of the PET tracer [F-18]FEAnGA in C6 gliomas was increased significantly by 15-70%, depending on the treatment. Histochemical analysis of the tumors indicated that carmustine and TNF-alpha treatment caused a larger necrotic area with the absence of infiltrating immune cells, whereas doxorubicin induced an increase in leukocyte infiltration. These results were confirmed by flow cytometry. In conclusion, the present study demonstrates that a single dose of a cytostatic agent is able to increase the release of beta-GUS. The release in beta-GUS can be monitored by [F-18]FEAnGA PET in a noninvasive manner. This study may open the way to a two-step chemotherapy prodrug approach, in which tumors are treated with a single dose of a cytostatic drug prior to prodrug treatment.

引用

页码：3277 / 3285

页数：9

共 21 条

[1] In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O-β-D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging β-Glucuronidase Activity in a Tumor/Inflammation Rodent Model [J].